Disease Spotlight: Prostate Cancer

The combination of the imaging agent Locametz and the targeted radioligand therapy Pluvicto may allow targeted treatment and mortality risk reduction in patients with prostate cancer.

Interesting questions raised by a paper that compared the use of 18F-fluciclovine with 68Ga-PSMA-11 imaging modalities to detect biochemical relapse in prostate cancer and implications for integrating newer techniques into clinical practice.

Reactions to key findings from an article by Birgit Pernthaler, et al, that compared the use of 18F-fluciclovine with 68Ga-PSMA-11 imaging modalities to detect biochemical relapse in prostate cancer.

Drs Steven Finkelstein and Louis J. Mazzarelli highlight data revealed in the article “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Birgit Pernthaler, et al.

Drs Steven Finkelstein and Louis J. Mazzarelli comment on limitations associated with conventional imaging modalities in prostate cancer and highlight the roles of newer tests such as 18F-fluciclovine and 68Ga-PSMA-11.

PSMA PET is highly robust in identifying prostate cancer lesions which are otherwise deemed unremarkable.